April 23, 2024

Information on Clozapine

Latest Update April 25, 2024 – FDA will be hosting an in-person advisory committee meeting in fall 2024 to discuss reevaluation of the Clozapine risk evaluation […]
April 23, 2024

Ongoing | Cancer Accelerated Approvals

Ojemda (tovorafenib) Patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 […]
April 23, 2024

FDA Roundup: April 23, 2024

For Immediate Release: April 23, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the […]
April 23, 2024

2023 Warning Letters – Health Fraud

12/23/2023 East Fork Cultivars Center for Drug Evaluation and Research | CDER Finished Pharmaceuticals/Unapproved New Drug/Misbranded 12/20/2023 Hua Da Trading, Inc. Center for Drug Evaluation and […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0